Roles of Bile-Derived Exosomes in Hepatobiliary Disease

Yuan Yao,1,2 Dechao Jiao,1 Zhaonian Li,1,2 Xueliang Zhou,1,2 Jing Li,1,2 Zaoqu Liu,1 and Xinwei Han1

1Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052 Henan, China
2Academy of Medical Sciences, Zhengzhou University, Zhengzhou, 450052 Henan, China

Correspondence should be addressed to Xinwei Han; 13592583911@163.com

Received 12 August 2020; Revised 23 December 2020; Accepted 6 January 2021; Published 15 January 2021

Academic Editor: Jin Shui Pan

Copyright © 2021 Yuan Yao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Exosomes are vesicles with a diameter of 30-150 nm produced by living cells and secreted into the extracellular matrix. Exosomes mediate cellular communication by carrying active molecules, such as nucleic acids, proteins, and liposomes. Although exosomes are found in various body fluids, little is known about bile-derived exosomes. This review is the first to summarize the methods of bile storage and isolation of biliary exosomes, highlighting the roles of bile-derived exosomes, especially exosomal noncoding RNAs, in physiological and disease states and discussing their potential clinical applications.

1. Background

Exosomes are vesicles secreted into the extracellular environment by the fusion of specific endosomes, i.e., multivesicular bodies (MVBs), with the plasma membrane; exosomes mediate cell-to-cell communication during many biological processes, including tumour progression and immune response [1, 2]. Exosomes are small (30–150 nm) vesicles with unique RNA and protein cargoes. The stability of noncoding RNAs in the exosomes is higher than that in body fluids; this increased stability may be due to the membranous structure of the outer vesicle surface. Exosomes are found in a wide variety of body fluids, including blood, urine, breast milk, amniotic fluid, saliva, cerebrospinal fluid, and ascites. Extensive distribution of exosomes has facilitated their extraction and research. Bile is a special body fluid that is secreted by the liver cells, stored in the gallbladder, and discharged into the duodenum through the bile duct to facilitate the digestion of fat and the absorption of fat-soluble vitamins. As a microenvironment for the growth of tumour cells, bile may contain a relatively high amount of tumour-related proteins and genes secreted by tumour cells and may thus be used as a source of early tumour markers and therapeutic targets for hepatobiliary diseases [3–5]. To date, exosomes in bile have been relatively rarely investigated, which may be due to the difficulty of bile collection and poorly developed methods of extraction of the exosomes from bile. This review summarizes feasible extraction methods and mechanisms and highlights potential clinical applications of biliary exosomes.

2. Overview of Exosomes

In the 1990s, Johnstone et al. identified a membranous vesicle in the supernatant of in vitro culture medium of sheep erythrocytes and named it an exosome [6, 7]. Exosomes are formed by intracellular lysosomal microparticles and released into the extracellular matrix after the fusion of the extracellular plasma membrane layer with the outer membrane of the vesicles. Exosomes are membranous vesicles secreted by living cells with a diameter of approximately 30-150 nm and a typical morphology. Exosomes contain mainly fusion proteins and transporters, heat shock proteins (e.g., HSP70), CD proteins, phospholipases, and other lipid-related proteins [8, 9]. These proteins constitute the structural basis for exosome identification (Western blotting). Moreover, exosomes from various cell sources have significant heterogeneity, and the cargo loaded in the exosomes varies depending on cell type and/or different states of the same cell [10]. Exosomes carry proteins, miRNAs, lncRNAs, circRNAs, and mRNAs involved in cell signal transduction and participate in the regulation of important activities and cell-to-cell communication [11, 12]. Furthermore, exosomes...
3. Isolation and Characterization of Human Biliary Exosomes

3.1. Collection and Storage of Bile. Bile samples are obtained at ERCP or at the time of percutaneous manipulation of biliary tubes by interventional radiology (IR). Then, the samples are placed into a sterile collection tube. In previous studies, bile was always extracted without contrast injection to ensure exosome yield and to reduce the interference of irrelevant factors [17–19]. Cell debris and precipitates are then removed by cryogenic centrifugation (3000 × g, 10 min, 4°C). Finally, the supernatant is transferred to cryogenic cryopreservation tubes and stored in a -80°C freezer or in liquid nitrogen. Theoretically, pretreatment of bile before storage is necessary because most bile specimens are relatively viscous and contain many impurities. Therefore, centrifugation of the samples before storage conveniently facilitates the extraction and identification of the exosomes in later stages. Bile extraction is a moderately traumatic operation that requires close attention to the physical condition of the patient. The whole experimental study must conform to the appropriate standards and ethical guidelines.

3.2. Isolation of Human Bile Exosomes. Due to the lack of current exosome extraction standards, the process varies depending on body fluids (Figure 2). For example, in the case of isolation of salivary exosomes, the low viscosity of the saliva prevents it from passing through the membrane [20], and filter membranes are not used to extract urinary exosomes [21]. Compared to exosomes in other body fluids, milk exosomes require repeated extraction during the first step, which may be related to the globular fat layer in the milk [22]. However, the characteristics of exosomes differ in different reports, and the experimental conditions should be determined according to the natural conditions and sample characteristics. Despite certain specifics, the principles of exosome extraction from various body fluids are similar. In summary, low-speed centrifugation is used to remove cell debris and impurities; then, the substances that differ in diameter from the exosomes are removed by filtration through a membrane. Then, the exosomes are pelleted by ultrafast centrifugation. Finally, the exosomes enriched in the pellet can be washed with PBS. Specific samples may require pretreatment. For example, bile samples need to be centrifuged at a low speed after collection to facilitate storage, reduce the degradation of the exosomes, and ensure that the collected material is free from microbial contamination [23].

This approach has some limitations. Ultracentrifugation requires relatively specific equipment, and the process is operationally complex and requires professional training. Limited capacity of the centrifuge rotors enables processing of only a small number of samples at one time. However, the exosomes obtained by this continuous centrifugation and filtration method are undoubtedly of high purity.

Certain kits, such as ExoQuick (produced by System Biosciences), separate poorly soluble exosomes from the solution by precipitation and enable their collection by low-speed centrifugation or filtration. HansaBioMed (http://www
3.3. Characterization of Human Biliary Exosomes. Exosomes can be directly visualized by transmission electron microscopy (TEM) due to their structural characteristics, i.e., 30-150 nm spherical structures, and the diameter of the exosomes in the images corresponds to exosomal characteristics, thus enabling their preliminary identification [24]. Additionally, nanoparticle tracking analysis (NTA) has been recognized as one of the means for exosome characterization in the field of exosome research. NTA is based on tracking and analysis of the Brownian motion of individual particles and calculations of the hydrodynamic diameter and concentration of the nanoparticles based on the Stokes-Einstein equation. These NTA principles provide information only on particle size distribution and particle concentration and cannot be used to distinguish exosomes from other particles. Therefore, exosome-specific markers are fluorescently labelled and are used to determine the content of specific subgroups of exosomes. Moreover, exosomes originate from intracellular sources and contain many membrane fusion and transport proteins (GTPases), tetraspanins (e.g., CD9, CD63, and CD81), and proteins involved in the biogenesis of multivesicular bodies (Alix and TSG101) [25–27]. The results obtained by Western blotting (WB) contribute to the identification of exosomes based on these specific proteins.

4. Pathophysiological Mechanism of Biliary Exosomes

A previous study confirmed that biliary exosomes attached to the primary cilia in the bile duct cause a decrease in the ratio of phosphorylated ERK1/2 to total ERK1/2, an increase in the expression of miR-15A, and a decrease in the proliferation of bile duct cells [28] (Figure 3); the study was performed using healthy animal models and demonstrated that enrichment of exosomes in the primary cilia is required for ciliary function; however, details of exosomal substances and mechanisms of action of the exosomes were not thoroughly discussed. The downstream target of miR-15A was not verified, and a
tumour model was not established. We can only infer that exosomes secreted by the tumour cells in bile activated the ERK pathway based on the previously demonstrated role of the ERK pathway in the tumours, which involves promotion of cell proliferation [29]. However, because of differences in tumour types and heterogeneity of the exosomes, additional experiments are needed to confirm this hypothesis. A recent study reported that circ-CCAC1, which is expressed at a high level in biliary exosomes of patients with cholangiocarcinoma, can enhance the transcription of CAMLG in cholangiocarcinoma cells by absorbing miR-514a-5p and upregulating YY1, and CAMLG promotes the progression of the tumour cells. circ-CCAC1 can be incorporated into the exosomes and subsequently is ingested by vascular endothelial cells. This circRNA enters the cytoplasm of the cells and binds to EZH2 to reduce its intranuclear transport, decrease the formation of H3K27me3, and promote the transcription of SH3GL2 to increase the level of SH3GL2, which can negatively regulate ZO-1/occludin; these events eventually destroy the endothelial barrier function and promote tumour angiogenesis [30]. Rafal et al. [31] have confirmed that bile duct ligation (BDL) increased release of Hh-containing exosome-enriched microparticles into plasma and bile, and all microparticles induced similar Hh-dependent changes in SEC gene expression, suggesting a novel mechanism for cirrhotic vasculopathy. Moreover, animal experiments have shown that biliary exosomes can promote the proliferation of CD4 and CD8 T cells and monocytes in the liver and can inhibit avian leucosis virus subgroup J (ALV-J) [32]. The study included only in vitro cell experiments without in vivo verification and did not further explore the mechanism of the effect of biliary exosomes on the immune function. However, the results provide an interesting reference with regard to the investigations of the relationships between biliary exosomes and immunity.

Nagashima et al. [33] have also confirmed that exosomes isolated from HEV-infected cells contained detectable levels of viral ORF2 and ORF3 proteins, and the capsids of HEV particles were also individually covered by lipid membranes that resemble the lipid membranes of exosomes, which all help to elucidate the entry mechanisms and receptors for HEV infection in the future.

Most studies focused on the cargoes carried by the exosomes and specifically concentrated on noncoding RNAs. We have reviewed recent publications on the mechanism of exosome delivery in all types of humoral sources, and the findings are presented in detail in Table 1. In summary, exosomes might follow some relatively classical pathways, such as the ERK and/or FAK/Src pathways, while the main protagonists, noncoding RNAs, may mediate tumour proliferation, angiogenesis, tumour metastasis, and tumour cell apoptosis.

The majority of the recent studies have been primarily...
interested in miRNAs and lncRNAs. The main mechanism of action of exosome-derived miRNAs includes miRNA recognition of the binding sites on the 3′-UTR of mRNAs of the target genes according to the seed sequences (5′-terminal 2-8 nucleotides) carrying RISCs. Transcriptional repression and mRNA cleavage or degradation eventually inhibit downstream gene expression or weaken or eliminate downstream gene function, resulting in indirect regulation of physiological and pathological states [34]. The secondary structure of exosome-derived lncRNAs results in protein binding, which can cause chromatin remodelling and influence the functions of transcription factors. Moreover, lncRNAs can bind to linear miRNA to indirectly influence mRNA expression or directly bind to mRNA to influence mRNA translation, fragmentation, and degradation [35, 36].

Similar to circulating noncoding RNA, the function of the whole system becomes complex due to the external structure of the exosomes and other substances present in the exosomes, such as DNA and proteins. For example, does the structure of external vesicles enhance their targeting ability? Is there any protection against the degradation of internal noncoding RNA? Interestingly, tetrascans on the exosome surface have been reported to play an important role in the targeting of exosomes [37–39]. This family of proteins may contribute to precisely targeted therapies. Moreover, some studies have confirmed that noncoding RNAs wrapped by exosomes do not degrade after incubation at room temperature for 24 h or longer [18]. This advantage gives exosomes greater potential for use as tumour biomarkers when compared with circulating noncoding RNAs. Moreover, RNA-digesting enzymes cannot degrade RNAs carried by the exosomes with intact membrane [40]. Conversely, does the combination of membranous structures influence the binding of noncoding RNAs to target genes? Most exosomes ingested by the cells have been shown to be targeted to lysosomes, where the exosomes are subsequently degraded via biological processes [41, 42]. Does the destination of the exosomes influence the function of their internal cargoes? Additional studies are needed to answer these questions. In general, the biogenesis of exosomes is complex, varies depending on the content and cell type, and may be influenced by signalling and pathological stimuli received by the cells. Moreover, studies on exosome production and secretion should consider factors and activities that influence the mechanism and kinetics of early exosome sorting [43–45]. Currently, there are no specific reports describing the mechanism of

**Figure 4:** The mechanism of action of biliary exosomes in cholangiocarcinoma. circ-CCAC1, which is highly expressed in bile exosomes of patients with cholangiocarcinoma, can enhance the transcription of CAMLG in cholangiocarcinoma cells by sponging miR-514a-5p and upregulating YY1; CAMLG promotes the progression of tumour cells. circ-CCAC1 can be loaded into the exosomes and uptaken by vascular endothelial cells. This circRNA enters the cytoplasm and binds to EZH2 to reduce its intranuclear transport, decrease the formation of H3K27me3, and promote the transcription of SH3GL2; then, SH3GL2 level is increased to negatively regulate ZO-1/occludin and eventually destroy endothelial barrier function, promoting tumour angiogenesis.
| Source                | Disease type         | Related molecule           | Signalling pathway | Function                                                                 | Ref. |
|----------------------|----------------------|---------------------------|--------------------|--------------------------------------------------------------------------|------|
| Bile                 | Normal physiology    | miR-15A                   | ERK                | Exosomes in bile interact with primary cilia to reduce the proliferation of bile duct cells through the ERK pathway and miR-15A. | [28] |
|                      | Normal physiology    | ALV-J                     | —                  | Biliary exosomes promote the proliferation of CD4\(^+\) and CD8\(^+\) T cells and monocytes in the liver, and can inhibit ALV-J. | [32] |
| Bile, cell line       | Cholangiocarcinoma   | circ-CCAC1/miR-514a-5p/YY1/CAMLG axis EZH2/SH3GL2/ZO-1/occludin | —                  | The circ-CCAC1-carrying EVs released by cholangiocarcinoma cells were absorbed by endothelial cells. circ-CCAC1 was able to destroy vascular barrier and angiogenesis via the regulation of EZH2/SH3GL2/ZO-1/occludin. | [30] |
| Serum, cell line      | Prostate cancer      | PKM2, CXCL12              | HIF-1\(\alpha\)    | Exosome-mediated PKM2 upregulated BMSC CXCL12 by HIF-1\(\alpha\)-dependent fashion to complete bone metastasis of prostate cancer. | [69] |
|                      | Liver fibrosis       | IncRNA-H19                | —                  | Exosomal IncRNA-H19 promotes cholestatic liver fibrosis by promoting the differentiation and activation of HSCs. | [70] |
|                      | Cholestatic liver    | IncRNA-H19                | ERK1/2, AMPK, SHP  | Uptake of H19-carrying exosomes from cholangiocytes suppresses SHP expression by inhibiting promoter activity and destabilizing SHP mRNA in hepatocytes. Downregulation of SHP expression results in increase of bile acid synthesis and eventually causes cholestatic liver injury. | [71] |
|                      | injury               |                          |                    | Hypoxic exosomal IncRNA-UCA1 promoted tumour growth and progression in vitro and in vivo through EMT. | [72] |
|                      | Bladder tumour       | IncRNA-UCA1              | EMT                | Exosome-secreted IncRNA-UCA1 from BCC cells promoted tumour growth and progression. |        |
|                      | Hepatocellular       | LOXL4                     | FAK/Src pathway    | Exosome-mediated secretion of LOXL4 by modulating the FAK/Src pathways and angiogenesis in HCC, plays the role of tumour metastasis. | [73] |
|                      | carcinoma            |                          |                    | Gastric cancer-derived exosomes carry high mobility group box-1 (HMGB1), which interacts with Toll-like receptor 4 (TLR4) to activate NF-\(\kappa\)B and induce neutrophil autophagy, thereby promoting gastric cancer cell migration. | [74] |
|                      | Tissue, cell line    | HMGB1/TLR4               | NF-\(\kappa\)B pathway | Endogenous annexin A1 (ANXA1) is released as a component of intestinal epithelial EVs that activate wound repair circuits. | [75] |
|                      | Gastric cancer       |                          |                    | Endogenous annexin A1 (ANXA1) is released as a component of intestinal epithelial EVs that activate wound repair circuits. | [75] |
|                      | Inflammatory bowel   | ANXA1                     | FPR1 and FPR2/ALX  | Exosome-secreted IncRNA-UCA1 from BCC cells promoted tumour growth and progression. |        |
|                      | disease              |                          |                    | Endogenous annexin A1 (ANXA1) is released as a component of intestinal epithelial EVs that activate wound repair circuits. | [75] |
|                      | Clear cell renal cell carcinoma | miR-19b-3p, PTEN, CD103, E-cadherin, N-cadherin, vimentin, twist | EMT                | CSC exosomes transport miR-19b-3p to CCRC cells and initiate EMT to promote metastasis. CD103 enables tumour to target lung. | [76] |
|                      | Osteochondral defects | CD73, IL-1\(\beta\), TNF-\(\alpha\) | AKT, ERK           | MSC exosomes achieve osteochondral regeneration through coordinated mobilization of multiple cell types and activation of multiple cellular processes. | [77] |
| Urine                | Diabetes             | DMBT1                     | /                  | USC-exos may promote angiogenesis by transferring DMBT1 protein. | [78] |
| Breast               | Breast cancer        | TGF\(\beta\)2, E-cadherin, alpha-smooth muscle actin (\(\alpha\)-SMA), filamentous- (F-) actin, vimentin | EMT                | Breast exosomes with high TGF\(\beta\)2 expression can induce changes in benign and malignant breast epithelial cells. | [79] |
exosome sorting in the liver or bile duct, and the applicability of general sorting rules to these structures requires confirmation. Additionally, some studies have reported that in cell culture, exosomes that are not fully released and/or are captured by the same cell require specific attention [46, 47]. Biliary exosomes may be influenced by similar fluctuating factors. Furthermore, the mechanisms governing the uptake may vary from source to source, and the mechanisms of the release of the contents of internalized exosomes are incompletely understood [48].

Because of the diversity of exosome components, the effects of noncoding RNAs may be mediated by internal proteins, lipids, or DNA; the complexity of the whole process suggests that noncoding RNAs originating from exosomes may interfere with or promote any part of the process. Thus, studies of the mechanisms of action of biliary exosomes require reasonable extrapolation based on the exosomes characterized in other sources and complete description of the related biological processes, including secretion, transport, and uptake of the exosomes, and functions that are influenced by considerable heterogeneity of the exosomes [49, 50]. Studies on biliary exosomes are limited; the mechanisms associated with biliary exosomes may be similar to those of exosomes originating from other humoral sources, and these similarities have to be gradually validated in future studies. Importantly, unique mechanisms associated with biliary exosomes may be used to facilitate the studies of biliary diseases and identify accurate treatments.

5. Potential Applications of Biliary Exosomes

5.1. Potential Biomarkers of Diseases. Bile is the most directly accessible internal environment for bile duct-related diseases. There is no doubt that all types of cytokines and extracellular vesicles may be enriched in bile regardless of bile duct-related tumours or inflammation levels, providing a theoretical basis for the studies of biomarkers. The presence of exosomes in bile has been confirmed, and these exosomes contain abundant microRNA species that are stable in bile. Thus, a diagnostic panel was developed based on bile duct carcinoma-associated microRNAs. The ROC curve confirmed a panel sensitivity of 67% and a specificity of 96% [18]. Interestingly, five miRNAs were included in this study, and a mathematical model was used to simulate a panel of five miRNAs for diagnosis, which improved the diagnostic sensitivity. However, too many molecules blindly included in a panel will reduce its specificity. Furthermore, the IncRNA species in biliary exosomes were sequenced and subjected to the GO, KEGG pathway, coexpression, receiver operating characteristic curve, and survival analyses, demonstrating that the levels of ENST00000588480.1 and ENST00517758.1 IncRNAs were significantly increased in the cholangiocarcinoma (CCA) group compared with those in the control group (benign obstruction). A combined diagnosis based on these two IncRNAs substantially improved the sensitivity and specificity of the diagnostic panel. Other studies demonstrated that these two molecules are associated with tumour staging and prognosis. In addition, a series of biogenic analyses and predictions was performed, and the p53 signalling pathway was found to be the most significantly different in the cells and associated with these IncRNAs, providing a reference for future mechanistic studies and targeted therapy. Thus, IncRNAs from exosomes may be used as potential biomarkers and therapeutic targets [19]. In addition, a comparison of biliary exosome concentrations in the case of benign and malignant biliary tract obstruction enabled researchers to define a concentration threshold, which served as the basis for discrimination between benign and malignant biliary tract obstruction. Surprisingly, the study compared the diagnostic accuracy of serum exosomes and biliary exosomes, and the accuracy of biliary exosomes was shown to be substantially higher than that of the serum exosomes (100% vs. 63.3%). Similarly, the levels of biliary exosomal circ-CCAC1, serum exosomal circ-CCAC1, and serum CA-199 (AUC = 0.857, 0.759, and 0.737, respectively) were compared, and the results showed that biliary exosomes are preferred for the diagnosis of cholangiocarcinoma, and the diagnostic effect was enhanced if biliary exosomes were combined with serum CA-199 [30]. These results suggest that biliary exosomes have good clinical application potential.

A number of recent studies have verified potential applications of the exosomes from various sources as biomarkers (Table 2). Analysis of the data indicated that biliary exosomes and exosomes from other body fluids have common stability factors and similar abilities for the transport of relatively specific substances, such as RNA, DNA, and proteins. The membrane of the vesicle-based structure of the exosomes provides better protection for the substances that otherwise are directly exposed to body fluids, and this protection may reduce the degradation of the effectors substances in complex humoral environments and maintain their levels at effective and detectable doses. Moreover, some studies confirmed that tumour-derived exosomes are involved in the formation of the microenvironment before tumour metastasis and may thus serve as early warning signals of tumour metastasis [51]. Furthermore, exosomes mediate intercellular communication and carry a large amount of information about tumours; thus, exosomes may be relatively more sensitive to the progress of the tumours and to prognosis after treatment. Apparently, biliary exosomes are more accurate predictors of biliary tract-related diseases than other humoral exosomes. Furthermore, bile is the most directly accessible internal environment for these diseases, especially for CCA. Therefore, exosomes secreted by tumour cells are expected to be enriched in bile, suggesting their use for early diagnosis. Moreover, the relatively closed internal environment of the bile duct reduces the effect of other interfering factors. Hence, additional studies are needed to confirm the effectiveness and specificity of the exosomes as biomarkers that can be included in the development of new panels for diagnosis and prognosis of various diseases.

However, these conclusions cannot be blindly generalized or extended. A recent study on the diagnosis of pancreatic duct adenocarcinoma (PDAC) confirmed that a higher frequency of mutant KRAS was detected in the circulating exosome-derived DNA in PDAC patients and in the vast majority of healthy subjects [52]. This result suggests that generalization of the findings obtained using exosome-
derived molecules requires scrutiny and validation by a rigorous experimental process.

5.2. Potential Therapeutic Applications for Diseases. Exosomes are membranous vesicles with a diameter of 30-150 nm secreted by cells. Exosomes play important roles in cell-to-cell communication through the biological processes involved in their generation and secretion and targeting of receptor cells [53, 54]. The structure and functions of exosomes suggest that they have great therapeutic potential [55]. For example, intracellular exosome generation and extracellular exosome release enable exosomes to serve as carriers of intracellular substances and as specific biomarkers that reflect the state of the cells or tissues. The characteristics of targeting receptor cells enable precise drug delivery via exosomes to the target cells or tissues, which may increase the concentration of the drugs in the target tissues and thus reduce the toxicity and side effects of the drugs in other tissues. Furthermore, the outer membrane of these vesicles may increase the stability of the therapeutic system, preventing drug degradation and irrelevant deposition [56]. Recent studies on therapeutic exosomes have been divided into two categories: natural exosomes produced within an organism and externally modified exosomes obtained from conditioned medium in specific cultures or special external treatments (drugs or gene modification) [55]. Although the mechanism of exosome therapy is not well understood, its potential is gradually being demonstrated.

Table 2: Biomarkers in exosomes from various humoral sources.

| System           | Diseases                          | Source          | Molecule                          | Application | AUC value | Ref. |
|------------------|-----------------------------------|-----------------|-----------------------------------|-------------|-----------|------|
| Digestive system| Malignant biliary stenosis        | Bile            | EV concentrations                 | Diagnosis   | 1.0       | [17] |
|                  | Cholangiocarcinoma                | Bile            | Multi-miR markers                 | Diagnosis   | —         | [18] |
|                  | Cholangiocarcinoma                | Bile            | ENST00000588480.1, ENST00000517758.1 | Diagnosis   | 0.709     | [19] |
|                  | Liver cancer                      | Plasma          | Exosomal circ-CCAC1               | Diagnosis   | 0.857     | [30] |
|                  | Pancreas cancer                   | Serum tissue    | GPC1(+) crExos                    | Diagnosis   | 1.0       | [81] |
|                  | Pancreas cancer                   | Blood           | Glypican-1, CD63                  | Diagnosis   | 0.989     | [82] |
|                  | Gastric cancer                    | Plasma culture media | Exosomal IncUEGC1                | Diagnosis   | 0.876     | [83] |
| Urogenital system| High-grade prostate cancer        | Urine           | ExoDx Prostate IntelliScore       | Diagnosis   | 0.70      | [84] |
|                  | Prostate cancer                   | Urine           | miR-196a-5p, miR-501-3p            | Diagnosis   | 0.73, 0.69| [85] |
|                  | High-grade prostate cancer        | Urine           | ExoDx Prostate IntelliScore       | Diagnosis   | 0.77      | [86] |
|                  | Prostate cancer                   | Urine           | Exosomal metabolites              | Diagnosis   | —         | [87] |
|                  | Castration-resistant prostate cancer | Plasma       | miR-1290, miR-375                 | Prognosis   | 0.68      | [88] |
|                  | Bladder cancer                    | Urine           | MALAT1,PCAT-1, SPRY4-IT1          | Diagnosis   | 0.813     | [89] |
|                  | Cervical cancer                   | Plasma          | Let-7d-3p, miR-30d-5p             | Diagnosis   | 0.828     | [90] |
|                  | Breast cancer                     | Serum           | miR-21, miR-222, miR-200c         | Diagnosis   | —         | [91] |
| Respiratory system| Lung cancer                       | Plasma          | CD151, CD171, TSPAN8             | Diagnosis   | 0.68, 0.60, 0.60 | [92] |
|                  | Asthma                            | Culture medium  | EPO, MBP, ECP                    | Diagnosis   | —         | [16] |
| Nervous system   | Alzheimer’s disease               | Blood CSF       | Abeta42, T-tau, P-T181-tau        | Diagnosis   | 0.98      | [93] |
|                  | Relapsing remitting multiple sclerosis | CSF            | Exosomal proteins                 | Diagnosis   | —         | [94] |
| Other diseases   | Melanoma                          | Plasma          | Melanoma-derived exosomes         | Diagnosis   | —         | [95] |
|                  | Pheochromocytoma                  | Serum           | Exosomal dsDNA                    | Diagnosis   | —         | [96] |
|                  | Paraganglioma                     | Blood           | Abeta1-42, P-T181-tau, P-S396-tau | Diagnosis   | —         | [97] |
|                  | Preeclampsia                      | Plasma          | PGF, CTB-TIMP1, AV-PAI1           | Diagnosis   | 0.96      | [98] |
|                  | Multiple myeloma                  | Serum           | Let-7b, miR-18a                   | Diagnosis   | —         | [99] |
Exosomes with certain characteristics can be ideal therapeutic tools. However, certain limitations have been demonstrated. For example, it is difficult to track the exosome transport process and distribution in vivo. Fortunately, some researchers have developed a means of direct labelling of the exosomes through gas-coated gold nanoparticles (GNPs) and identified the distribution of these exosomes using computed tomography to determine the best drug delivery routes [57]. Another limitation to the therapeutic effect of exosomes is due to unidentified substances in body fluids that can invade and affect exosomes. Interestingly, this limitation can be overcome by enveloping exosomes with nanofilms composed of supramolecular complexes of ferric ions (Fe^{3+}) and tannic acid. Additionally, nanofilms enable the retention of the inherent size and chemical composition of the exosomes thereby promoting the controlled release of drugs [58]. The clinical application of exosomes faces the challenge of insufficient targeting, and a research team has developed a dual-function exosome-based superparamagnetic nanoparticle cluster as a delivery vehicle for targeting drugs for cancer therapy; this vehicle manifested greater responsiveness than that of a single superparamagnetic nanoparticle, thus enhancing the targeting ability of the tumours [59]. The application of the exosomes in clinical treatment is expected to encounter a series of problems, including complex operation due to high difficulty and high cost, which will require further studies to resolve.

The c(RGDDyK) peptide was conjugated to the exosomes in a certain manner, and these exosomes were used as carriers to deliver curcumin in a targeted manner in an ischaemic stroke model in mice; this treatment produced anti-inflammatory effects in the brain and overcame the inability of drugs to pass the blood-brain barrier [60]. Similarly, macrophage exosomes were used as natural nanocarriers to deliver proteins for the treatment of inflammatory encephalopathy [61]. The carrier must be improved during the application process based on the immediate situation to enhance transport efficiency and effect. This improvement requires the synchronous development of nanoengineering technology. Cargo-loaded exosomes have broad therapeutic prospects. For example, docosahexaenoic acid (DHA) induced miR-23b and miR-320b overexpression by changing the exosome secretion levels and reducing the expression of the angiogenesis-related target genes (PLAU, AMOTL1, NRP1, and ETS2) to ultimately inhibit tumour progression [62]. In addition, exosome therapy may be closely associated with tumour immunity. Some studies reported that phagocytosis of tumour cells by phagocytes was inhibited because of the interaction between CD47 on the tumour surface and the signal regulatory protein (SIRPalpha) on macrophages [63, 64].

**Figure 5:** Potential clinical application of exosomes. Exosomes are produced by living cells, carry a variety of active molecules, and are ubiquitously present in various body fluids. Exosomes may be detected in the microenvironment before tumour metastasis and reflect tumour proliferation and metastasis; therefore, they can be used as biomarkers for early diagnosis and prognosis of tumours. Because of specialized vesicle structure, exosomes are stable carriers of therapeutic drugs with increased targeting ability. Therapeutic exosomes can be divided into two categories: natural exosomes secreted directly in body fluids and artificially engineered exosomes.
The interaction between CD47 and SIRPalpha was antagonized using SIRPalpha-exosomes to promote phagocytosis of the tumour cells [65]. Moreover, CpG DNA-modified exosomes (CpG-SAV-exo) were generated and used to form an exosome-based tumour antigen-adjuvant codelivery system, which may be used in cancer immunotherapy [66]. Interestingly, exosomes may also be used to explain the therapeutic effect of exercise on metabolic diseases, such as obesity and type 2 diabetes (T2DM). For example, a study suggested that the benefits of exercise are mediated by exosomes and/or microvesicles that function in an autocrine, paracrine, and/or endocrine manner and have therapeutic effects on obesity and diabetes [67]. Various new technologies were used to generate artificial therapeutic exosomes, mimicking the structural characteristics of endogenous exosomes. These exosomes were modified according to the needs of individual patients and may have broad therapeutic significance [68].

Bile is a special fluid secreted by the liver and transported through the bile ducts. Bile does not reach the whole body; therefore, characteristics of bile can be used to accurately diagnose diseases of the biliary tract. There is no doubt that biliary exosomes may have possible therapeutic uses and effects based on principles described in the present review. Bile is the most directly accessible contact environment in the diseases of the bile duct system; thus, bile-specific exosomes may produce better therapeutic effects. For example, circ-CCAC1 in biliary exosomes may play an important role in CCA progression; therefore, suppression of circ-CCAC1 expression or blocking the transmission of exosomal circ-CCAC1 might be a novel therapeutic strategy for CCA [30]. Furthermore, bile enters the duodenum via the bile duct, providing certain therapeutic potential for intestinal diseases. Physiological circulation through the liver and intestine may also produce lasting effects. However, extraction of bile is a relatively complex and difficult process, which is, to an extent, the main limiting factor of studies on biliary exosomes.

6. Conclusion and Perspectives

In brief, we reviewed the biogenesis and development of exosomes, provided the initial theoretical basis for future mechanistic studies, summarized the isolation and identification of biliary exosomes for the first time, and highlighted the mechanisms and principles of the effects of exosomes in bile and the clinical application potential of the exosomes (Figure 5). We described nonbiliary exosomes as models and reasonably extended the results of the breakthrough studies to bile-derived exosomes. These considerations are based on the premise of a systematically elaborated mechanism and application of exosomes. Moreover, we provided references for future studies on biliary exosomes via a literature review that includes a general research strategy and theoretical basis. The studies of biliary exosomes remain limited due to the moderately traumatic acquisition of bile and numerous bile components, such as bile salts, which may influence the effects of the exosomes. Additionally, the range of bile action is relatively limited, in contrast to that of the blood, which circulates throughout the body. However, these unresolved problems do not diminish the potential value of biliary exosomes in diagnosis and treatment of biliary tract-related diseases; additional in-depth studies are needed to thoroughly investigate biliary exosomes.

Abbreviations

- MVBS: Multivesicular bodies
- EVs: Extracellular vesicles
- miRNAs: MicroRNA
- lncRNA: Long noncoding RNA
- ERCP: Endoscopic retrograde cholangiopancreatography
- IR: Interventional radiology
- PBS: Phosphate-buffered saline
- TEM: Transmission electron microscopy
- NTA: Nanoparticle tracking analysis
- WB: Western blotting
- ALV-J: Avian leucosis virus subgroup
- RISC: RNA-induced silencing complex
- CCA: Cholangiocarcinoma
- PDAC: Pancreatic ductal adenocarcinoma
- KRAS: Kirsten rat sarcoma viral oncogene
- GNPs: Gold nanoparticles
- DHA: Docosahexaenoic acid
- SIRPalpha: Signal regulatory protein
- CpG-SAV-exo: CpG DNA-modified exosome
- T2DM: Type 2 diabetes
- PKM2: Pyruvate kinase isozyme type M2
- BMSC: Bone marrow stromal cell
- HSC: Hepatic stellate cell
- EMT: Epithelial-mesenchymal transition
- LOXL4: Lysyl oxidase like protein 4
- HCC: Hepatocellular carcinoma
- HMGB1: High mobility group box-1
- TLR4: Toll-like receptor 4
- ANXA1: Annexin A1
- FPR: Formyl peptide receptor
- PTEN: Gene of phosphate and tension homology deleted on chromosome ten
- CSC: Cancer stem cell
- CCRCC: Clear cell renal cell carcinoma
- TNF-α: Tumour necrosis factor alpha
- TGFβ2: Transforming growth factor beta 2
- α-SMA: Alpha-smooth muscle actin
- MSC: Mesenchymal stem cell
- IL-1β: Interleukin-1β
- DMBT1: Deleted in malignant brain tumours
- AUC: Area under curve.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no competing interests.


Authors’ Contributions

Yuan Yao and Dechao Jiao contributed equally to this work.

Acknowledgments

This study was supported by the Henan Medical Science and Technology Public Relations Program (Grant Number: SB201902014).

References

[1] Z. Lu, B. Zuo, R. Jing et al., “Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models,” *Journal of Hepatology*, vol. 67, no. 4, pp. 739–748, 2017.

[2] L. Li, K. Piontek, M. Ishida et al., “Extracellular vesicles carry microRNA-195 to intrahepatic cholangiocarcinoma and improve survival in a rat model,” *Hepatology*, vol. 65, no. 2, pp. 501–514, 2016.

[3] S. A. Gradilone, S. P. O’Hara, T. V. Masyuk, M. J. Pisarello, and N. F. LaRusso, “MicroRNAs and benign biliary tract diseases,” *Seminars in Liver Disease*, vol. 35, no. 1, pp. 26–35, 2015.

[4] J. J. Marin, L. Bujanda, and J. M. Banales, “MicroRNAs and cholestatic liver diseases,” *Current Opinion in Gastroenterology*, vol. 30, no. 3, pp. 303–309, 2014.

[5] S. A. Gradilone, “Extracellular vesicles as therapeutic carriers of microRNAs for cholangiocarcinoma,” *Hepatology*, vol. 65, no. 2, pp. 404–406, 2016.

[6] R. M. Johnstone, A. Bianchini, and K. Teng, “Reticulocyte maturation and exosome release: transferrin receptor containing exosomes shows multiple plasma membrane functions,” *Blood*, vol. 74, no. 5, pp. 1844–1851, 1989.

[7] R. M. Johnstone, M. Adam, J. R. Hammonds, L. Orr, and C. Turbide, “Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes),” *The Journal of Biological Chemistry*, vol. 262, no. 19, pp. 9412–9420, 1987.

[8] J. Gobbo, G. Marcion, M. Cordonnier et al., “Restoring anticancer immune response by targeting tumor-derived exosomes with a HSP70 peptide aptamer,” *Journal of the National Cancer Institute*, vol. 108, no. 3, 2016.

[9] C. Subra, D. Grand, K. Laulagnier et al., “Exosome accounts for vesicle-mediated transcellular transport of activatable phospholipases and prostaglandins,” *Journal of Lipid Research*, vol. 51, no. 8, pp. 2105–2120, 2010.

[10] N. Chaput and C. Théry, “Exosomes: immune properties and potential clinical implementations,” *Seminars in Immunopathology*, vol. 33, no. 5, pp. 419–440, 2011.

[11] D. Prieto, N. Sotelo, N. Seija et al., “S100-A9 protein in exosomes from chronic lymphocytic leukemia cells promotes NF-κB activity during disease progression,” *Blood*, vol. 130, no. 6, pp. 777–788, 2017.

[12] H. Zhang, T. Deng, S. Ge et al., “Exosome circRNA secreted from adipocytes promotes the growth of hepatocellular carcinoma by targeting deubiquitination-related USP7,” *Oncogene*, vol. 38, no. 15, pp. 2844–2859, 2019.

[13] G. Yu, H. Jung, Y. Y. Kang, and H. Mok, “Comparative evaluation of cell- and serum-derived exosomes to deliver immune stimulators to lymph nodes,” *Biomaterials*, vol. 162, pp. 71–81, 2018.

[14] M. K. S. Tang, P. Y. K. Yue, P. P. Ip et al., “Soluble E-cadherin promotes tumor angiogenesis and localizes to exosome surface,” *Nature Communications*, vol. 9, no. 1, p. 2270, 2018.

[15] P. J. Wermuth, S. Piera-Velazquez, J. Rosenbloom, and S. A. Jimenez, “Existing and novel biomarkers for precision medicine in systemic sclerosis,” *Nature Reviews Rheumatology*, vol. 14, no. 7, pp. 421–432, 2018.

[16] C. Mazzeo, J. A. Cañas, M. P. Zafra et al., “Exosome secretion by eosinophils: a possible role in asthma pathogenesis,” *The Journal of Allergy and Clinical Immunology*, vol. 135, no. 6, pp. 1603–1613, 2015.

[17] V. Severino, J. M. Dumonceau, M. Delhaye et al., “Extracellular vesicles in bile as markers of malignant biliary stenoses,” *Hepatology*, vol. 60, no. 3, pp. 896–907, 2014.

[18] X. Ge, Y. Wang, J. Nie et al., “The diagnostic/prognostic potential and molecular functions of long non-coding RNAs in the exosomes derived from the bile of human cholangiocarcinoma,” *OncoTarget*, vol. 8, no. 41, pp. 69995–70005, 2017.

[19] V. Palanisamy, S. Sharma, A. Deshpande, H. Zhou, J. Gimzewski, and D. T. Wong, “Nanostructural and transcriptomic analyses of human saliva derived exosomes,” *PLoS One*, vol. 5, no. 1, article e5877, 2010.

[20] R. Golan-Gerstl, Y. Elbaum Shiff, V. Moshayoff, D. Schecter, D. Leshkowitz, and S. Reif, “Characterization and biological function of milk-derived miRNAs,” *Molecular Nutrition & Food Research*, vol. 61, no. 10, p. 1700009, 2017.

[21] H. Izumi, M. Tsuda, Y. Sato et al., “Bovine milk exosomes contain microRNA and mRNA and are taken up by human macrophages,” *Journal of Dairy Science*, vol. 98, no. 5, pp. 2920–2933, 2015.

[22] I. K. Yan, V. X. Berdah, and T. Patel, “Isolation of extracellular RNA from bile,” *Methods in Molecular Biology*, vol. 1740, pp. 59–67, 2018.

[23] A. Kotrbová, K. Stěpka, M. Maška et al., “TEM ExosomeAnalyzer: a computer-assisted software tool for quantitative evaluation of extracellular vesicles in transmission electron microscopy images,” *Journal of Extracellular Vesicles*, vol. 8, no. 1, p. 1560808, 2019.

[24] E. Lozano-Andrés, S. F. Libregts, V. Toribio et al., “Tetraspanin-decorated extracellular vesicle-mimetics as a novel adaptable reference material,” *Journal of Extracellular Vesicles*, vol. 8, no. 1, p. 1573052, 2019.

[25] V. Hyenne, M. Labouesse, and J. G. Goetz, “The small GTPase Rabin7 orchestrates MVB biogenesis and exosome secretion,” *Small GTPases*, vol. 9, no. 6, pp. 445–451, 2017.

[26] R. P. Carney, S. Hazari, M. Colquhoun et al., “Characterization and biological function of milk-derived miRNAs,” *Molecular Nutrition & Food Research*, vol. 61, no. 10, p. 1700009, 2017.

[27] R. M. Johnstone, A. Bianchini, and K. Teng, “Reticulocyte maturation and exosome release: transferrin receptor containing exosomes shows multiple plasma membrane functions,” *Blood*, vol. 74, no. 5, pp. 1844–1851, 1989.

[28] J. Gobbo, G. Marcion, M. Cordonnier et al., “Restoring anticancer immune response by targeting tumor-derived exosomes with a HSP70 peptide aptamer,” *Journal of the National Cancer Institute*, vol. 108, no. 3, 2016.

[29] C. Subra, D. Grand, K. Laulagnier et al., “Exosome accounts for vesicle-mediated transcellular transport of activatable phospholipases and prostaglandins,” *Journal of Lipid Research*, vol. 51, no. 8, pp. 2105–2120, 2010.

[30] N. Chaput and C. Théry, “Exosomes: immune properties and potential clinical implementations,” *Seminars in Immunopathology*, vol. 33, no. 5, pp. 419–440, 2011.

[31] D. Prieto, N. Sotelo, N. Seija et al., “S100-A9 protein in exosomes from chronic lymphocytic leukemia cells promotes NF-κB activity during disease progression,” *Blood*, vol. 130, no. 6, pp. 777–788, 2017.

[32] H. Zhang, T. Deng, S. Ge et al., “Exosome circRNA secreted from adipocytes promotes the growth of hepatocellular carcinoma by targeting deubiquitination-related USP7,” *Oncogene*, vol. 38, no. 15, pp. 2844–2859, 2019.

[33] G. Yu, H. Jung, Y. Y. Kang, and H. Mok, “Comparative evaluation of cell- and serum-derived exosomes to deliver immune stimulators to lymph nodes,” *Biomaterials*, vol. 162, pp. 71–81, 2018.
MAPK/ERK activation,” *Digestive and liver disease*, vol. 41, no. 12, pp. 875–880, 2009.

[30] Y. Xu, K. Leng, Y. Yao et al., "A novel circular RNA, circ-CCAC1, contributes to CCA progression, induces angiogenesis, and disrupts vascular endothelial barriers," *Hepatology*, 2020.

[31] R. P. Witek, L. Yang, R. Liu et al., "Liver cell-derived microparticles activate hedgehog signaling and alter gene expression in hepatic endothelial cells," *Gastroenterology*, vol. 136, no. 1, pp. 320–330.e2, 2009.

[32] Y. Wang, G. Wang, Z. Wang, H. Zhang, L. Zhang, and Z. Cheng, "Chicken biliary exosomes enhance CD4(+)T proliferation and inhibit ALV-J replication in liver," *Biochemistry and Cell Biology*, vol. 92, no. 2, pp. 145–151, 2014.

[33] S. Nagashima, M. Takahashi, T. Kobayashi et al., "Characterization of the quasi-enveloped hepatitis E virus particles released by the cellular exosomal pathway," *Journal of Virology*, vol. 91, no. 22, 2017.

[34] S. Atay, S. Banskota, J. Crow, G. Sethi, L. Rink, and A. K. Godwin, "Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion," *Proceedings of the National Academy of Sciences*, vol. 111, no. 2, pp. 711–716, 2014.

[35] K. Shyu, B. Wang, C. Pan, W. Fang, and C. Lin, "Hyperbaric oxygen boosts long noncoding RNA MALAT1 exosome secretion to suppress microRNA-92a expression in therapeutic angiogenesis," *International Journal of Cardiology*, vol. 274, pp. 271–278, 2019.

[36] L. Pan, W. Liang, M. Fu et al., "Exosomes-mediated transfer of long noncoding RNA ZFAS1 promotes gastric cancer progression," *Journal of cancer research and clinical oncology*, vol. 143, no. 6, pp. 991–1004, 2017.

[37] X. Gao, N. Ran, X. Dong et al., "Anchor peptide captures, targets, and loads exosomes of diverse origins for diagnostics and therapy," *Science Translational Medicine*, vol. 10, no. 444, p. t195, 2018.

[38] S. Rana, S. Yue, D. Stadel, and M. Zöller, "Toward tailored exosomes: the exosomal tetraspacin web contributes to target cell selection," *The International Journal of Biochemistry & Cell Biology*, vol. 44, no. 9, pp. 1574–1584, 2012.

[39] S. Rana and M. Zöller, "Exosome target cell selection and the importance of exosomal tetraspans: a hypothesis," *Biochemical Society*, vol. 39, no. 2, pp. 559–562, 2011.

[40] S. Keller, J. Ridinger, A. Rupp, J. W. Janssen, and P. Altevogt, "Body fluid derived exosomes as a novel template for clinical diagnostics," *Journal of Translational Medicine*, vol. 9, no. 1, p. 86, 2011.

[41] W. Chen, X. Wen, M. Latzel et al., "Nanoscale characterization of carrier dynamic and surface passivation in InGaN/GaN multiple quantum wells on GaN nanorods," *ACS Applied Materials & Interfaces*, vol. 8, no. 46, pp. 31887–31893, 2016.

[42] T. Tian, Y. Wang, H. Wang, Z. Zhu, and Z. Xiao, "Visualizing of the cellular uptake and intracellular trafficking of exosomes by live-cell microscopy," *Journal of Cellular Biochemistry*, vol. 111, no. 2, pp. 488–496, 2010.

[43] C. Villarroya-Beltri, C. Gutiérrez-Vázquez, F. Sánchez-Cabo et al., "Sumoylated hnRNP2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs," *Nature Communications*, vol. 4, no. 1, p. 2980, 2013.

[44] C. Hsu, Y. Morohashi, S. Yoshimura et al., "Regulation of exosome secretion by Rab35 and its GTPase-activating proteins TBC1D10A–C," *The Journal of Cell Biology*, vol. 189, no. 2, pp. 223–232, 2010.

[45] A. Savina, M. Furlán, M. Vidal, and M. I. Colombo, "Exosome release is regulated by a calcium-dependent mechanism in K562 cells," *The Journal of Biological Chemistry*, vol. 278, no. 22, pp. 20083–20090, 2003.

[46] A. Matsumoto, Y. Takahashi, M. Nishikawa et al., "Accelerated growth of B16BL6 tumor in mice through efficient uptake of their own exosomes by B16BL6 cells," *Cancer Science*, vol. 108, no. 9, pp. 1803–1810, 2017.

[47] J. R. Edgar, P. T. Manna, S. Nishimura, G. Banting, and M. S. Robinson, "Tetherin is an exosomal tether," *eLife*, vol. 5, 2016.

[48] C. Bissig and J. Gruenberg, "ALIX and the multivesicular endosome: ALIX in wonderland," *Trends in Cell Biology*, vol. 24, no. 1, pp. 19–25, 2014.

[49] E. Willms, H. J. Johansson, I. Mäger et al., "Cells release subpopulations of exosomes with distinct molecular and biological properties," *Scientific Reports*, vol. 6, no. 1, p. 22519, 2016.

[50] Z. J. Smith, C. Lee, T. Rojalin et al., "Single exosome study reveals subpopulations distributed among cell lines with variability related to membrane content," *Journal of Extracellular Vesicles*, vol. 4, no. 1, p. 28533, 2015.

[51] H. Peinado, H. Zhang, I. R. Matei et al., "Pre-metastatic niches: organ-specific homes for metastases," *Nature Reviews. Cancer*, vol. 17, no. 5, pp. 302–317, 2017.

[52] K. Allenson, J. Castillo, F. A. San Lucas et al., "High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients," *Annals of Oncology*, vol. 28, no. 4, pp. 741–747, 2017.

[53] L. Mao, X. Li, S. Gong et al., "Serum exosomes contain ECRG4 mRNA that suppresses tumor growth via inhibition of genes involved in inflammation, cell proliferation, and angiogenesis," *Cancer Gene Therapy*, vol. 25, no. 9-10, pp. 248–259, 2018.

[54] J. C. Akers, D. Gonda, R. Kim, B. S. Carter, and C. C. Chen, "Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies," *Journal of Neuro-Oncology*, vol. 113, no. 1, pp. 1–11, 2013.

[55] R. S. Conlan, S. Pisano, M. I. Oliveira, M. Ferrari, and P. I. Mendes, "Exosomes as reconfigurable therapeutic systems," *Trends in Molecular Medicine*, vol. 23, no. 7, pp. 636–650, 2017.

[56] B. Yang, Y. Chen, and J. Shi, "Exosome biochemistry and advanced nanotechnology for next-generation theranostic platforms," *Advanced Materials*, vol. 31, no. 2, p. 1802896, 2019.

[57] O. Betzer, N. Perets, A. Angel et al., "In vivo neuroimaging of exosomes using gold nanoparticles," *ACS Nano*, vol. 11, no. 11, pp. 10883–10893, 2017.

[58] S. Kumar, I. J. Michael, J. Park, S. Granick, and Y. K. Cho, "Cloaked exosomes: biocompatible, durable, and degradable encapsulation," *Small*, vol. 14, no. 34, article e1802052, 2018.

[59] H. Qi, C. Liu, L. Long et al., "Blood exosomes endowed with magnetic and targeting properties for cancer therapy," *ACS Nano*, vol. 10, no. 3, pp. 3323–3333, 2016.

[60] T. Tian, H. X. Zhang, C. P. He et al., "Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy," *Biomaterials*, vol. 150, pp. 137–149, 2018.

[61] D. Yuan, Y. Zhao, W. A. Banks et al., "Macrophage exosomes as natural nanocarriers for protein delivery to inflamed brain," *Biomaterials*, vol. 142, pp. 1–12, 2017.
proliferation, attenuating apoptosis and modulating immune reactivity,” *Biomaterials*, vol. 156, pp. 16–27, 2018.

[78] C. Y. Chen, S. S. Rao, L. Ren et al., “Exosomal DMBT1 from human urine-derived stem cells facilitates diabetic wound repair by promoting angiogenesis,” *Theranostics*, vol. 8, no. 6, pp. 1607–1623, 2018.

[79] W. Qin, Y. Tsukasaki, S. Dasgupta, N. Mukhopadhyay, M. Ikebe, and E. R. Sauter, “Exosomes in human breast milk promote EMT,” *Clinical Cancer Research*, vol. 22, no. 17, pp. 4517–4524, 2016.

[80] L. Zhu, J. Li, Y. Gong et al., “Exosomal tRNA-derived small RNA as a promising biomarker for cancer diagnosis,” *Molecular Cancer*, vol. 18, no. 1, p. 74, 2019.

[81] S. A. Melo, L. B. Luecke, C. Kahler et al., “Glycapan-1 identifies cancer exosomes and detects early gastric cancer,” *Nature*, vol. 523, no. 7559, pp. 177–182, 2015.

[82] J. M. Lewis, A. D. Vyas, Y. Qiu, K. S. Messer, R. White, and M. J. Heller, “Integrated analysis of exosomal protein biomarkers on alternating current electrokinetic chips enables rapid detection of pancreatic cancer in patient blood,” *ACS Nano*, vol. 12, no. 4, pp. 3311–3320, 2018.

[83] L. Y. Lin, L. Yang, Q. Zeng et al., “Tumor-originated exosomal LncUEGC1 as a circulating biomarker for early-stage gastric cancer,” *Molecular Cancer*, vol. 17, no. 1, p. 84, 2018.

[84] J. McKiernan, M. J. Donovan, E. Margolis et al., “A prospective adaptive utility trial to validate performance of a novel urine exosome gene expression assay to predict high-grade prostate cancer in patients with prostate-specific antigen 2-10 ng/ml at initial biopsy,” *European Urology*, vol. 74, no. 6, pp. 731–738, 2018.

[85] M. Rodriguez, C. Bajo-Santos, N. P. Hessvik et al., “Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes,” *Molecular Cancer*, vol. 16, no. 1, p. 156, 2017.

[86] J. McKiernan, M. J. Donovan, V. O’Neill et al., “A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy,” *JAMA Oncology*, vol. 2, no. 7, pp. 882–889, 2016.

[87] M. Clos-García, A. Loizaga-Iriarte, P. Zuñiga-Garcia et al., “Metabolic alterations in urine extracellular vesicles are associated to prostate cancer pathogenesis and progression,” *Journal of extracellular vesicles*, vol. 7, no. 1, p. 1470042, 2018.

[88] X. Huang, T. Yuan, M. Liang et al., “Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer,” *European Urology*, vol. 67, no. 1, pp. 33–41, 2015.

[89] Y. Zhan, L. Du, L. Wang et al., “Expression signatures of exosomal long non-coding RNAs in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer,” *Molecular Cancer*, vol. 17, no. 1, p. 142, 2018.

[90] M. Zheng, L. Hou, Y. Ma et al., “Exosomal let-7d-3p and miR-30d-5p as diagnostic biomarkers for non-invasive screening of cervical cancer and its precursors,” *Molecular Cancer*, vol. 18, no. 1, p. 76, 2019.

[91] J. U. Lee, W. H. Kim, H. S. Lee, K. H. Park, and S. J. Sim, “Quantitative and specific detection of exosomal miRNAs for accurate diagnosis of breast cancer using a surface-enhanced Raman scattering sensor based on plasmonic head-flocked gold nanopillars,” *Small*, vol. 15, no. 17, article e1804968, 2019.

[92] B. Sandfeld-Paulsen, K. R. Jakobsen, R. Bæk et al., “Exosomal proteins as diagnostic biomarkers in lung cancer,” *Journal of Thoracic Oncology*, vol. 11, no. 10, pp. 1701–1710, 2016.
[93] L. Jia, Q. Qiu, H. Zhang et al., "Concordance between the assessment of Aβ42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid," *Alzheimers Dement*, vol. 15, no. 8, pp. 1071–1080, 2019.

[94] J. L. Welton, S. Loveless, T. Stone, C. von Ruhland, N. P. Robertson, and A. Clayton, "Cerebrospinal fluid extracellular vesicle enrichment for protein biomarker discovery in neurological disease; multiple sclerosis," *Journal of extracellular vesicles*, vol. 6, no. 1, article 1369805, 2017.

[95] P. Sharma, S. Ludwig, L. Muller et al., "Immunoadfinity-based isolation of melanoma cell-derived exosomes from plasma of patients with melanoma," *Journal of Extracellular Vesicles*, vol. 7, no. 1, p. 1435138, 2018.

[96] L. Wang, Y. Li, X. Guan, J. Zhao, L. Shen, and J. Liu, "Exosomal double-stranded DNA as a biomarker for the diagnosis and preoperative assessment of pheochromocytoma and paraganglioma," *Molecular Cancer*, vol. 17, no. 1, p. 128, 2018.

[97] E. D. Hamlett, E. J. Goetzl, A. Ledreux et al., "Neuronal exosomes reveal Alzheimer’s disease biomarkers in Down syndrome," *Alzheimers Dement*, vol. 13, no. 5, pp. 541–549, 2017.

[98] K. H. Tan, S. S. Tan, M. J. Ng et al., "Extracellular vesicles yield predictive pre-eclampsia biomarkers," *Journal of extracellular vesicles*, vol. 6, no. 1, p. 1408390, 2017.

[99] S. Manier, C. J. Liu, H. Avet-Loiseau et al., "Prognostic role of circulating exosomal miRNAs in multiple myeloma," *Blood*, vol. 129, no. 17, pp. 2429–2436, 2017.